The SOUL Trial Changes Everything: Oral Semaglutide and the New Standard for Cardiovascular Risk Reduction in Type 2 Diabetes
For years, the conversation around GLP-1 receptor agonists in type 2 diabetes centered almost entirely on glucose lowering. Then came a series of landmark cardiovascular outcomes trials — LEADER, SUSTAIN-6, PIONEER 6 — and the paradigm began to shift. But until recently, one practical barrier remained: most GLP-1 receptor agonists required subcutaneous injection, limiting uptake […]
